Rapport Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-27.2M | $-28.8M | $1.6M | $3.5M |
| FY2024 | $-64.8M | $-67.2M | $2.4M | $10.2M |
| FY2025 | $-87.5M | $-88.1M | $616.0K | $18.9M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-27.2M | $-28.8M | $1.6M | $3.5M |
| FY2024 | $-64.8M | $-67.2M | $2.4M | $10.2M |
| FY2025 | $-87.5M | $-88.1M | $616.0K | $18.9M |